Find clinical trials for Non-Hodgkin Lymphoma in Hanyang, Seoul
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Non-Hodgkin Lymphoma trials near Hanyang, Seoul, KOR:
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma...
Phase 1, Phase 2
Seoul, Korea, Republic of and 68 other locations
This is an open-label, multiple ascending dose (MAD), phase 1 study in adult patients with relapsed or refractory (R/R) B cell non-Hodgkin...
Phase 1
Seoul, South Korea and 15 other locations
safety and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in participants with Relapsed/Refractory B-cell Non...
Phase 1, Phase 2
Seoul, South Korea and 20 other locations
Determine MTD based on the safety and tolerability of AT101 and the RP2D for patients with recurrent or non-reactive B-cell NHL....
Phase 1, Phase 2
Seoul, Seoul, South Korea
is focused on patients with previously treated aggressive B-cell non-Hodgkin lymphoma whose cancer has stopped responding ...
Phase 3
Seoul, South Korea and 92 other locations
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purp-...
Phase 2
Seoul, Seoul Teugbyeolsi, South Korea and 75 other locations
Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed orig...
Phase 4
Seoul, South Korea and 34 other locations
The main purpose of this study is to characterize safety and to determine the recommended phase 2 dose (RP2D) for JNJ-88998377 (Part A: Dose Escalati...
Phase 1
Seoul, South Korea and 18 other locations
of adult participants with relapsed or refractory (r/r) B-Cell non-Hodgkin lymphoma (B-NHL) or frontline high-risk diffuse...
Phase 1, Phase 2
Seoul, South Korea and 29 other locations
pharmacokinetic, pharmacodynamic, and clinical activity of AZD0486, a CD19 x CD3 T-cell engaging bispecific antibody, in subjects with B-cell non...
Phase 1
Seoul, South Korea and 28 other locations
Clinical trials
Research sites
Resources
Legal